Aryl boronates are among the most widely used synthetic intermediates in the pharmaceutical and agrochemical industries, both in R&D and commercial manufacture.1 Historically these key building blocks have been made using transition metal (Pd, Cu, Ni) catalysed cross coupling reactions between an appropriate aryl halide (usually bromide,  iodide or activated chlorides) and an alkoyboron species.2 Efforts to